MedTrace Logo

Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy

NCT02694562 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).

Conditions

  • Colorectal Carcinoma

Interventions

DEVICE

40um Embozene TANDEM Microspheres

40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Franco Orsi, MD · European Institute of Oncology (Milan Italy)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02694562 on ClinicalTrials.gov